Literature DB >> 7545535

Ultrastructural and immunohistochemical observations on intralobular fibroblasts of human breast, with observations on the CD34 antigen.

K Yamazaki1, B P Eyden.   

Abstract

Understanding the diverse pathological processes which are initiated in the ultimate organizational units of the mammary parenchyma--the lobules and ductules--will to a large extent be based on understanding the normal breast. During the routine diagnostic evaluation of 11 surgical specimens for a variety of benign and malignant breast lesions, grossly normal mammary parenchyma, subsequently confirmed as histologically normal by light microscopy, was sampled for this purpose. Tissue was studied by histology, light microscope immunohistochemistry, transmission electron microscopy, scanning electron microscopy, and ultrastructural immunohistochemistry. A number of features hitherto disregarded in the literature are described in detail, or are elaborated with respect to earlier descriptions. These include: the presence of solitary cilia and lipid-rich residual bodies in intralobular fibroblasts, and the frequent association of inflammatory cells (lymphocytes, plasma cells, macrophages, mast cells) with the cell bodies and processes of fibroblasts. For the first time also, CD34, best known as an endothelial cell marker, has been demonstrated by ultrastructural immunohistochemistry on the cell surface of fibroblasts. Finally, scanning electron microscopy has demonstrated new features of the intercellular matrix in which the fibroblasts and inflammatory cells are located. The significance of these findings is discussed in terms of a postulated immune surveillance role of the mononuclear cells in collaboration with the fibroblasts.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545535

Source DB:  PubMed          Journal:  J Submicrosc Cytol Pathol        ISSN: 1122-9497


  8 in total

1.  CD34 positive stromal cells in gastric adenocarcinomas.

Authors:  H Nakayama; H Enzan; E Miyazaki; N Kuroda; K Naruse; H Kiyoku; M Toi; M Hiroi
Journal:  J Clin Pathol       Date:  2001-11       Impact factor: 3.411

2.  There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions.

Authors:  H Chauhan; A Abraham; J R A Phillips; J H Pringle; R A Walker; J L Jones
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

3.  Differential expression of CD34 in normal colorectal tissue, peritumoral inflammatory tissue, and tumour stroma.

Authors:  H Nakayama; H Enzan; E Miyazaki; N Kuroda; K Naruse; M Hiroi
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

4.  Uptake and intracytoplasmic storage of pigmented particles by human CD34+ stromal cells/telocytes: endocytic property of telocytes.

Authors:  Lucio Díaz-Flores; Ricardo Gutiérrez; M Pino García; Francisco J Sáez; Fernando Aparicio; Lucio Díaz-Flores; Juan F Madrid
Journal:  J Cell Mol Med       Date:  2014-09-30       Impact factor: 5.310

5.  Prognostic relevance of the loss of stromal CD34 positive fibroblasts in invasive lobular carcinoma of the breast.

Authors:  Christina C Westhoff; Paul Jank; Christian O Jacke; Ute-Susann Albert; Schokufe Ebrahimsade; Peter J Barth; Roland Moll
Journal:  Virchows Arch       Date:  2020-05-20       Impact factor: 4.064

Review 6.  Autoimmune Epithelitis and Chronic Inflammation in Sjögren's Syndrome-Related Dry Eye Disease.

Authors:  Yoko Ogawa; Tsutomu Takeuchi; Kazuo Tsubota
Journal:  Int J Mol Sci       Date:  2021-10-30       Impact factor: 5.923

Review 7.  Cascade of Inflammatory, Fibrotic Processes, and Stress-Induced Senescence in Chronic GVHD-Related Dry Eye Disease.

Authors:  Yoko Ogawa; Yutaka Kawakami; Kazuo Tsubota
Journal:  Int J Mol Sci       Date:  2021-06-06       Impact factor: 5.923

8.  Variable stromal periductular expression of CD34 and smooth muscle actin (SMA) in intraductal carcinoma of the breast.

Authors:  Xavier Catteau; Philippe Simon; Michel Vanhaeverbeek; Jean-Christophe Noël
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.